CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Cofactor Genomics›
News
Cofactor Genomics logo

Cofactor Genomics

Cofactor Genomics is a St. Louis-based diagnostics company that develops RNA-based tests to predict cancer immunotherapy response.

St. Louis, MO, US🇺🇸
Founded
2015
Accelerator
Y Combinator logoY CombinatorS15
Loading
Overview
Analysis
Compare
Fundraising
Employees
News
Library

Latest News About Cofactor Genomics

Veteran Oncologist and Cancer Center Leader Dr. Howard Bailey Joins Cofactor Genomics as Chief Medical Officer

Business Wire

Veteran Oncologist and Cancer Center Leader Dr. Howard Bailey Joins Cofactor Genomics as Chief Medical Officer

Former UW Carbone Cancer Center director Dr. Howard Bailey joined Cofactor Genomics as chief medical officer to guide clinical strategy as...

Jul 30, 2026

Cofactor Genomics Announces Strategic Investment by Labcorp and Ascension Ventures to Fuel Expansion of Its OncoPrism Immunotherapy Diagnostic Across U.S. Cancer Care Networks

Business Wire

Cofactor Genomics Announces Strategic Investment by Labcorp and Ascension Ventures to Fuel Expansion of Its OncoPrism Immunotherapy Diagnostic Across U.S. Cancer Care Networks

Cofactor Genomics announced strategic investments from Labcorp and Ascension Ventures to accelerate nationwide expansion and broaden...

Dec 15, 2025

Cofactor Genomics Announces CEO Transition in Preparation for Accelerated Commercial Growth and Increased Patient Access for OncoPrism

Business Wire

Cofactor Genomics Announces CEO Transition in Preparation for Accelerated Commercial Growth and Increased Patient Access for OncoPrism

Chris Parker was named CEO and board member of Cofactor Genomics while founder Jarret Glasscock transitions to president, CTO and board...

Jan 8, 2025

Precision Medicine Global Thought Leader Dr. Howard McLeod Joins Cofactor Genomics Advisory Board as Cofactor Brings OncoPrism Test to Partnered Hospitals

Business Wire

Precision Medicine Global Thought Leader Dr. Howard McLeod Joins Cofactor Genomics Advisory Board as Cofactor Brings OncoPrism Test to Partnered Hospitals

Dr. Howard McLeod joined Cofactor Genomics advisory board to help integrate precision medicine into partnered hospitals as the company...

Oct 29, 2024

Cofactor Genomics reports OncoPrism data

CAP Today

Cofactor Genomics reports OncoPrism data

Cofactor Genomics presented interim PREDAPT trial results showing OncoPrism reached 75 percent accuracy in predicting immunotherapy...

Oct 1, 2022